Vera Therapeutics names Nancy Boman as chief regulatory officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
July 9, 2026 8:00 AM EDTBRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer position. William Turner, current Chief Regulatory Officer of Vera Therapeutics, is planning to retire and transition to the role of Strategic Advisor in the third quarter of this year after a successful tenure at the company, including the recent accelerated approval of Vera Therapeutics first therapy in IgA nephropathy (IgAN), TRUTAKNAÂ (atacicept-vymj). Nancy Boman, M.D., Ph.D., will succeed Mr. Turner as Chief Regulatory... More
